|
業務類別
|
Biotechnology |
|
業務概覽
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan. |
| 公司地址
| 1500 Broadway, Suite 1401, New York, NY, USA, 10036 |
| 電話號碼
| +1 332 208-6102 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.nuvationbio.com |
| 員工數量
| 220 |
| Ms. Kerry Wentworth |
Chief Regulatory Officer |
-- |
08/04/2025 |
| Mr. Moses Makunje, C.P.A. |
Vice President, Finance and Principal Accounting Officer |
-- |
02/03/2026 |
| Mr. Philippe Sauvage |
Chief Financial Officer |
-- |
02/03/2026 |
| Dr. David T. Hung,M.D. |
Chairmain of the Board, President and Chief Executive Officer |
美元 609.84K |
02/03/2026 |
| Dr. David Liu, M.D.,PhD |
Chief Medical Officer |
-- |
08/04/2025 |
| Dr. David C. Hanley, PhD |
Chief Technical Operations Officer |
-- |
08/04/2025 |
| Ms. Stacy Markel |
Chief People Officer |
-- |
08/04/2025 |
| Ms. Colleen Sjogren |
Chief Commercial Officer |
美元 330.00K |
08/04/2025 |
| Dr. Gary Hattersley, PhD |
Chief Scientific Officer |
美元 502.98K |
08/04/2025 |
|
|
| Mr. Kim D. Blickenstaff |
Independent Director |
02/03/2026 |
| Dr. Xiangmin Cui, PhD |
Independent Director |
02/03/2026 |
| Mr. W. Anthony Vernon |
Independent Director |
02/03/2026 |
| Dr. Robert Mashal, M.D. |
Independent Director |
02/03/2026 |
| Dr. David T. Hung,M.D. |
Chairmain of the Board, President and Chief Executive Officer |
02/03/2026 |
| Ms. Kathryn E. Falberg |
Independent Director |
02/03/2026 |
| Mr. Robert B. Bazemore, Jr |
Lead Independent Director |
02/03/2026 |
|
|
|
|
